Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial

PURPOSE: Erlotinib has been the only targeted agent to show significantly improved outcomes in pancreatic adenocarcinoma when combined with gemcitabine. We aimed to evaluate whether the addition of oxaliplatin to a combination gemcitabine/erlotinib treatment conferred a clinical benefit in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sung Hee, Yun, Jina, Lee, Min-Young, Kim, Han Jo, Kim, Kyoung Ha, Kim, Se Hyung, Lee, Sang-Chul, Bae, Sang Byung, Kim, Chan Kyu, Lee, Namsu, Lee, Kyu Taek, Park, Seong Kyu, Lee, Yun Nah, Moon, Jong Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298866/
https://www.ncbi.nlm.nih.gov/pubmed/34296544
http://dx.doi.org/10.3349/ymj.2021.62.8.671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298866/
https://www.ncbi.nlm.nih.gov/pubmed/34296544
http://dx.doi.org/10.3349/ymj.2021.62.8.671

Ejemplares similares